Duality Advisers, LP Xencor Inc Transaction History

Duality Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$24.79 - $30.86 $548,602 - $682,931	22,130 New	22,130 $576,000
Q2 2022 Aug 08, 2022	SELL	$19.74 - $29.01 $48,520 - $71,306	-2,458 Reduced 8.08%	27,976 $766,000
Q1 2022 May 09, 2022	BUY	$26.68 - $41.63 $811,979 - $1.27 Million	30,434 New	30,434 $812,000
Q4 2021 Feb 02, 2022	SELL	$33.67 - $43.44 $656,598 - $847,123	-19,501 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$30.65 - $35.68 $63,230 - $73,607	-2,063 Reduced 9.57%	19,501 $637,000
Q2 2021 Aug 09, 2021	BUY	$34.33 - $44.68 $464,347 - $604,341	13,526 Added 168.28%	21,564 $744,000
Q1 2021 May 13, 2021	SELL	$40.81 - $53.88 $677,405 - $894,354	-16,599 Reduced 67.37%	8,038 $346,000
Q4 2020 Feb 09, 2021	BUY	$36.63 - $47.63 $902,453 - $1.17 Million	24,637 New	24,637 $1.08 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.